Sanofi SA Company Profile (NYSE:SNY)

About Sanofi SA

Sanofi SA logoSanofi SA, formerly Sanofi-Aventis, is a healthcare company engaged in the research, development, manufacture and marketing of therapeutic solutions. It operates through three segments: Pharmaceuticals, Human Vaccines (Vaccines) and Animal Health. The Pharmaceuticals segment consists of research, development, production and marketing of medicines, including those originating from Genzyme Corporation. Its pharmaceuticals portfolio consists of products and a range of prescription medicines, generic medicines and consumer health products. The Vaccines segment is dedicated to vaccines, including research, development, production and marketing. The Animal Health segment includes the research, development, production and marketing activities of Merial, which offers a range of medicines and vaccines for a range of animal species. It operates in the Other segment, which includes the effects of retained commitments. It operates through Regeneron Pharmaceuticals Inc.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Exchange: NYSE
  • Symbol: SNY
  • CUSIP:
Key Metrics:
  • Previous Close: $42.51
  • 50 Day Moving Average: $41.26
  • 200 Day Moving Average: $39.81
  • 52-Week Range: $36.81 - $44.50
  • Trailing P/E Ratio: 21.86
  • Foreward P/E Ratio: 13.02
  • P/E Growth: 1.97
  • Market Cap: $109.56B
  • Outstanding Shares: 2,565,800,000
  • Beta: 0.98
  • Net Margins: 13.66%
  • Return on Equity: 26.37%
  • Return on Assets: 14.46%
  • Debt-to-Equity Ratio: 0.27%
  • Current Ratio: 1.47%
  • Quick Ratio: 1.00%
Additional Links:
Companies Related to Sanofi SA:

Analyst Ratings

Consensus Ratings for Sanofi SA (NYSE:SNY) (?)
Ratings Breakdown: 1 Sell Rating, 6 Hold Ratings, 7 Buy Ratings
Consensus Rating:Hold (Score: 2.43)
Consensus Price Target: $75.50 (76.81% upside)

Analysts' Ratings History for Sanofi SA (NYSE:SNY)
DateFirmActionRatingPrice TargetDetails
2/9/2017NatixisUpgradeNeutral -> BuyView Rating Details
1/10/2017Leerink SwannReiterated RatingOutperformView Rating Details
1/8/2017Goldman Sachs Group, Inc. (The)Reiterated RatingHoldView Rating Details
11/29/2016Morgan StanleyUpgradeEqual Weight -> OverweightView Rating Details
9/23/2016Piper Jaffray CompaniesInitiated CoverageNeutralView Rating Details
9/15/2016J P Morgan Chase & CoReiterated RatingUnderweightView Rating Details
9/14/2016Jefferies Group LLCReiterated RatingHoldView Rating Details
9/13/2016BNP ParibasUpgradeUnderperform -> NeutralView Rating Details
9/8/2016Berenberg BankUpgradeHold -> BuyView Rating Details
6/28/2016Citigroup Inc.Reiterated RatingNeutralView Rating Details
5/12/2016Barclays PLCUpgradeEqual Weight -> OverweightView Rating Details
5/3/2016HSBC Holdings plcDowngradeBuy -> HoldView Rating Details
5/3/2016Bank of America CorpReiterated RatingBuy$58.00View Rating Details
4/12/2016Chardan CapitalReiterated RatingBuyView Rating Details
2/10/2016Sanford C. BernsteinLower Price TargetMarket-Perform$52.00 -> $45.00View Rating Details
12/16/2015Oddo SecuritiesDowngradeReduceView Rating Details
11/9/2015Bryan, Garnier & CoReiterated RatingBuy -> NeutralView Rating Details
9/16/2015Sarasin & PartnersUpgradeBuyView Rating Details
7/13/2015Deutsche Bank AGUpgradeBuyView Rating Details
4/15/2015Societe GeneraleInitiated CoverageBuyView Rating Details
(Data available from 2/25/2015 forward)


Earnings History for Sanofi SA (NYSE:SNY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/8/2017Q416$0.66$0.67$9.87 billion$8.88 billionViewN/AView Earnings Details
10/29/2015Q315$0.88$0.89ViewN/AView Earnings Details
4/30/2015Q115$0.61$0.73ViewN/AView Earnings Details
2/5/2015Q4$0.89$0.79ViewN/AView Earnings Details
7/31/2014Q2$0.79$0.72ViewN/AView Earnings Details
4/29/2014Q114$0.84$0.81ViewN/AView Earnings Details
2/6/2014Q4$0.88$0.93ViewN/AView Earnings Details
10/30/2013$1.01$0.93ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Sanofi SA (NYSE:SNY)
Current Year EPS Consensus Estimate: $3.08 EPS
Next Year EPS Consensus Estimate: $3.28 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162$0.65$0.72$0.69
Q2 20162$0.72$0.75$0.74
Q3 20161$0.91$0.91$0.91
Q4 20162$0.65$0.67$0.66
Q1 20171$0.75$0.75$0.75
Q2 20171$0.74$0.74$0.74
Q3 20171$0.90$0.90$0.90
Q4 20171$0.80$0.80$0.80
(Data provided by Zacks Investment Research)


Current Dividend Information for Sanofi SA (NYSE:SNY)
Annual Dividend:$1.12
Dividend Yield:2.62%
Dividend Growth:-2.50% (3 Year Average)
Payout Ratio:54.90% (Based on Trailing 12 Months of Earnings)
36.36% (Based on Current Year Consensus EPS Estimate)
34.15% (Based on Next Year Consensus EPS Estimate)

Dividend History for Sanofi SA (NYSE:SNY)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Sanofi SA (NYSE:SNY)
Insider Ownership Percentage: 1.00%
Institutional Ownership Percentage: 9.63%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/9/2014SanofiMajor ShareholderBuy195,000$308.27$60,112,650.00View SEC Filing  
7/8/2014SanofiMajor ShareholderBuy153,000$311.67$47,685,510.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Sanofi SA (NYSE:SNY)
News IconNews Buzz – WisdomTree Investments, Inc. (NASDAQ:WETF), Sanofi SA (ADR) (NYSE:SNY) - Daily News Journal (press release) (NYSE:SNY) - February 24 at 7:40 AM logo​Ipswich consultant’s biotech training program expands into Europe (NYSE:SNY) - February 23 at 1:09 AM
News IconSanofi (SNY) Increases Dividend to $1.58 Per Share (NYSE:SNY) - February 21 at 5:00 PM
News IconSanofi SA (SNY) Given Average Rating of "Hold" by Analysts (NYSE:SNY) - February 21 at 5:00 PM logoSanofi Pasteur: Why Human Vaccines Matter (NYSE:SNY) - February 21 at 5:00 PM logoWhat Happened to Sanofi’s Valuation after 4Q16? (NYSE:SNY) - February 21 at 5:00 PM logoSanofi SA given €85.00 PT by Jefferies Group LLC. neutral rating. (NYSE:SNY) - February 17 at 7:28 PM logoInside Sanofi’s Revenues in 4Q16 (NYSE:SNY) - February 17 at 7:28 PM logoRepatha Represents a Solid Growth Opportunity for Amgen in 2017 (NYSE:SNY) - February 16 at 7:42 PM logoNow that Olivier Brandicourt has been caught out, would $SNY like to issue an apology to the media? $JNJ $ATLN cc @ByMadeleineA (NYSE:SNY) - February 16 at 7:42 PM
News IconHow Sanofi blew its chance with Actelion (NYSE:SNY) - February 16 at 7:42 PM logoAmgen Looking to Broaden Leukemia Drug Blincyto's Label (NYSE:SNY) - February 16 at 7:42 PM logoGlaxoSmithKline’s Valuation Compared to Its Peers (NYSE:SNY) - February 15 at 6:06 AM logoIpsen to Acquire Select Consumer Healthcare Products from Sanofi (SNY) for EUR83M (NYSE:SNY) - February 14 at 6:26 AM logoSanofi Sells 5 Over-the-Counter Drugs for $88M (SNY) (NYSE:SNY) - February 14 at 6:26 AM logoSanofi to Sell 5 OTC Drugs to Ipsen for $88M (NYSE:SNY) - February 14 at 6:26 AM
News IconShares of Sanofi (SNY) Sees Large Inflow of Net Money Flow ... - Highland Mirror (NYSE:SNY) - February 13 at 8:11 AM logoIpsen to Acquire Select Consumer Healthcare Products from Sanofi (SNY) for EUR83M - (NYSE:SNY) - February 13 at 8:11 AM logoSanofi $SNY Shares Bought by GFS Advisors LLC (NYSE:SNY) - February 11 at 3:03 AM logoSanofi/Regeneron Praluent appeal could be decided as early as June say lawyers (NYSE:SNY) - February 11 at 3:03 AM logoSanofi :SNY-US: Earnings Analysis: 2016 By the Numbers : February 10, 2017 (NYSE:SNY) - February 11 at 3:03 AM logoSanofi $SNY Releases Quarterly Earnings Results, Beats Expectations By $0.01 .. (NYSE:SNY) - February 10 at 4:26 AM logoSanofi (SNY) Q4 Earnings In Line; Can Sell Praulent for Now (NYSE:SNY) - February 10 at 4:26 AM
News IconRegeneron Pharmaceuticals Inc (REGN) And Sanofi SA (ADR) (SNY) Loses On A Suit Blocking Amgen, Inc. (AMGN) From Selling Cholesterol Drug (NYSE:SNY) - February 9 at 1:40 PM logoRegeneron Gets 'Encouraging' Judicial Decision, Could Still Lose Appeal (NYSE:SNY) - February 9 at 12:34 PM logoSanofi Q4: Guidance Not Reassuring - Seeking Alpha (NYSE:SNY) - February 9 at 4:56 AM logoRegeneron (REGN) and Sanofi (SNY) Confirm Stay of Permanent Injunction for Praluent (AMGN) - (NYSE:SNY) - February 9 at 4:56 AM logoSanofi (SNY) Q4 2016 Results - Earnings Call Transcript - Seeking Alpha (NYSE:SNY) - February 9 at 4:56 AM logoSanofi Q4 sales up 3%; earnings up 137%; cash flow up 2%; shares up 2% premarket (NYSE:SNY) - February 8 at 7:50 AM
News IconSanofi SA (ADR) (SNY) Releases Earnings Results, Beats Expectations By $0.02 EPS - Highland Mirror (NYSE:SNY) - February 8 at 6:13 AM logoSanofi meets 4Q profit forecasts (NYSE:SNY) - February 8 at 6:13 AM logoSanofi's Valuation Is Not Compelling (NYSE:SNY) - February 6 at 8:03 PM
News IconResearch Reports Coverage on Drug Makers Stocks -- Sanofi, Impax Labs, Heron Therapeutics, and Biostar Pharma (NYSE:SNY) - February 6 at 8:19 AM logoSanofi $SNY Position Reduced by JNBA Financial Advisors (NYSE:SNY) - February 4 at 7:57 PM logoFourier Love All Around As Repatha Improves Outcomes (NYSE:SNY) - February 4 at 2:00 AM
News IconSanofi (NYSE:SNY) from Drug Manufacturers – Major – Todays Top Gains (NYSE:SNY) - February 4 at 2:00 AM logoSanofi Genzyme head weighs in on drug price debate (NYSE:SNY) - February 3 at 5:25 AM logoFDA OKs Sanofi's OTC allergy med Xyzal (NYSE:SNY) - February 2 at 3:18 AM logoSanofi's Xyzal Now Available OTC, GLPG Kicks Off ALBATROSS, PRXL Opens Wallet (NYSE:SNY) - February 2 at 3:18 AM logoAmgen Repatha Sales Surge Past Praluent After Ban (NYSE:SNY) - February 2 at 3:18 AM logoSanofi: Sanofi's Xyzal® Allergy 24HR Approved for Over-the-Counter Use in the United States (NYSE:SNY) - February 1 at 5:45 AM logo3:37 am Sanofi receives FDA approval for Xyzal as OTC treatment (NYSE:SNY) - February 1 at 5:45 AM logoInsulin makers sued over high prices (NYSE:SNY) - January 30 at 9:57 PM logoHagens Berman: Insulin Manufacturers Hit with Class-Action Lawsuit over Drug Price Inflation Scheme and RICO Violations – Time to Break up the Insulin Racket (NYSE:SNY) - January 30 at 9:57 PM logoThe makers of insulin are being accused of price-fixing in a class-action lawsuit (NYSE:SNY) - January 30 at 9:57 PM
News IconDrug Manufacturers – Major: Sanofi (NYSE:SNY) Position of the day (NYSE:SNY) - January 29 at 9:07 PM logoAfrezza Sales Still Low As MannKind Prepares For Investor Update (NYSE:SNY) - January 28 at 6:40 AM
News IconIs Sanofi (NYSE:SNY), a large market cap stock a smart buy? (NYSE:SNY) - January 28 at 6:40 AM logoSanofi left looking after J&J swipes Actelion in $30B deal $SNY $JNJ (NYSE:SNY) - January 27 at 3:41 AM
News IconLeading stocks in today’s market: Sanofi (NYSE:SNY) (NYSE:SNY) - January 27 at 3:41 AM


What is Sanofi SA's stock symbol?

Sanofi SA trades on the New York Stock Exchange (NYSE) under the ticker symbol "SNY."

How often does Sanofi SA pay dividends? What is the dividend yield for Sanofi SA?

Sanofi SA announced an annual dividend on Friday, February 17th. Investors of record on Monday, May 15th will be given a dividend of $1.5771 per share on Wednesday, June 7th. This represents a yield of 3.65%. The ex-dividend date of this dividend is Thursday, May 11th. This is a boost from Sanofi SA's previous annual dividend of $1.10.

Where is Sanofi SA's stock going? Where will Sanofi SA's stock price be in 2017?

14 brokers have issued 1 year price targets for Sanofi SA's stock. Their predictions range from $58.00 to $93.00. On average, they anticipate Sanofi SA's share price to reach $75.50 in the next twelve months.

Who owns Sanofi SA stock?

Sanofi SA's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Barrow Hanley Mewhinney & Strauss LLC (1.14%), Franklin Resources Inc. (0.82%), Hotchkis & Wiley Capital Management LLC (0.44%), FMR LLC (0.21%), Federated Investors Inc. PA (0.19%) and Senzar Asset Management LLC (0.05%).

Who sold Sanofi SA stock? Who is selling Sanofi SA stock?

Sanofi SA's stock was sold by a variety of institutional investors in the last quarter, including Barrow Hanley Mewhinney & Strauss LLC, Federated Investors Inc. PA, FMR LLC, Hotchkis & Wiley Capital Management LLC, Baird Financial Group Inc., Franklin Resources Inc., Envestnet Asset Management Inc. and Allianz Asset Management AG.

Who bought Sanofi SA stock? Who is buying Sanofi SA stock?

Sanofi SA's stock was bought by a variety of institutional investors in the last quarter, including Senzar Asset Management LLC, Paulson & CO. Inc., NWQ Investment Management Company LLC, Willis Investment Counsel, First Bank & Trust, Clark Capital Management Group Inc., Russell Investments Group Ltd. and Glacier Peak Capital LLC.

How do I buy Sanofi SA stock?

Shares of Sanofi SA can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Sanofi SA stock cost?

One share of Sanofi SA stock can currently be purchased for approximately $42.70.

Sanofi SA (NYSE:SNY) Chart for Saturday, February, 25, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Sanofi SA (NYSE:SNY)

Earnings History Chart

Earnings by Quarter for Sanofi SA (NYSE:SNY)

Dividend History Chart

Dividend Payments by Quarter for Sanofi SA (NYSE:SNY)

Last Updated on 2/25/2017 by Staff